Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations Routine +

Mountain Valley MD Advances Quicksome(TM) Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157

MVMD Advances Peptide Platform Ahead of July FDA Catalyst, Balance Sheet Fortified by Recent Financing

By The Northwire Desk — AI Analysis May 29, 2026 · 08:30 MVMD · 0.065 Mountain Valley MD Holdings Inc.
Executive Summary
  • Platform Advancement: Mountain Valley MD (MVMD) reports completion of initial formulation work on its patented Quicksome™ sublingual delivery platform across five key peptides (BPC-157, GHK-Cu, KPV, SNAP-8, retatrutide).
  • Validation Data: Technology validated to preserve heat-sensitive biological molecules outside refrigerated environments, meeting WHO Controlled Temperature Chain standards.
  • Regulatory Catalysts: Specific FDA Pharmacy Compounding Advisory Committee (PCAC) meetings identified: July 23-24, 2026 (reviewing seven peptides including BPC-157 and KPV) and February 2027 (five additional peptides).
  • Commercial Strategy: Focus remains on licensing and partnerships within North and South America rather than traditional pharmaceutical drug development pathways.
  • Market Context: Global peptide therapeutics market valued at $141 billion in 2025, projected to reach $295 billion by 2033.
Material Impact
  • Execution Confirmation: The news confirms the company is executing on its December 2025 commercialization strategy regarding licensing and platform advancement without pivoting to high-cost drug development.
  • Catalyst Visibility: Identification of specific FDA PCAC meeting dates (July 2026) provides a tangible near-term catalyst for investors, aligning with the regulatory timeline mentioned in previous updates.
  • Financial Stability: The recent April 2026 financing ($2M raised + $485k debt settlement) strengthens the balance sheet to support this R&D phase, reducing immediate capital risk compared to pre-financing periods.
  • Incremental Nature: While positive, the announcement details "initial formulation work" and validation rather than signed licensing agreements or revenue generation. It validates the technology but does not yet monetize it.
  • Market Expectations: The market likely anticipated this progress given the December 2025 update on Quicksome licensing with Circadian Wellness. Therefore, the news is viewed as positive confirmation of the existing narrative rather than a surprise inflection point.
MVMD · Price
Company Overview
  • Company: Mountain Valley MD Holdings Inc. (MVMD).
  • Flagship Projects:
    • Quicksome™: Patented sublingual rapid-dissolve delivery technology designed for systemic absorption without injection or refrigeration. Currently applied to nutraceuticals and compounded peptides.
    • Agrarius™: Agricultural signaling product showing yield increases in citrus, corn, sugarcane, soybeans, cotton, and potatoes (Brazil/Colombia trials).
    • Soluvec™ 1%: Ivermectin formulation for husbandry animals/aquatic species.
  • Development Stage: Quicksome is in commercialization/licensing phase; Agrarius has completed field trials with positive results; Soluvec is under strategic review for licensing partners.
Read the original news release →

More from Mountain Valley MD Holdings Inc.

Apr 15, 2026 · 08:00

MVMD Closes Financing to Fuel Agrarius Commercialization Amid Dilutive Share Issuance

Financings Mar 31, 2026 · 18:23

Mountain Valley arranges offering, two debt settlements

Financings Mar 31, 2026 · 08:30

MVMD Secures $2M Lifeline at Steep Discount as Warrant Strike Aligns with Recent Price Spike

Financings Mar 02, 2026 · 18:55

SEDAR Interim Financial Statements

None Dec 24, 2025 · 17:55

Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms

Production / Operations Dec 01, 2025 · 17:45

Mountain Valley MD Confirms Positive Agrarius Agricultural Trial Results, Advancing Toward Commercialization

Production / Operations